Condition
Invasive Meningococcal Disease
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04184336UnknownPrimary
Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada
NCT01732627Phase 2Completed
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
NCT01272180Phase 2CompletedPrimary
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
NCT01129518Phase 4CompletedPrimary
Can we Reduce the Number of Vaccine Injections for Children?
Showing all 4 trials